Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, August 01, 2019
FUJIFILM has completed the acquisition of Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark from Biogen.
read more
FUJIFILM Diosynth Biotechnologies has announced an expansion to its United Kingdom location through the creation of a new BioCampus.
read more
FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a Biologics Contract Development and Manufacturing Organization with experience focused on the development and manufacture of recombinant biopharmaceuticals including proteins, vaccines, and monoclonal ...
read more
FUJIFILM Diosynth Biotechnologies has commenced the planned capacity expansion of its Flexible Biomanufacturing Facility at its College Station, Texas location.
read more
Wednesday, August 27, 2014
FUJIFILM Diosynth Biotechnologies has announced continued expansion of its cell culture manufacturing capabilities with the addition of two 2000L single-use bioreactors. One each of these is being installed at the company's sites in Research Triangle...
read more
Wednesday, April 26, 2017
Fujifilm Corporation will increase production capacity by investing approximately $130 million in the United States and UK to expand the business of its BioCDMO Division.
read more
Monday, November 06, 2017
FUJIFILM is to invest a total of 3.2 billion yen on its CDMO sites in the U.S. and the U.K. in order to accelerate the expansion of the company's business for developing and manufacturing biopharmaceuticals under contract for other parties.
read more
FUJIFILM announced an initial $10M USD investment to establish a full scale, fully integrated continuous processing facility for non-GMP manufacture of biopharmaceuticals at its Billingham, UK location.
read more
Fujifilm Diosynth Biotechnologies has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
read more
Tuesday, November 22, 2022
FUJIFILM Corporation announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will be operated by FUJIFILM Irvine Scientific,
read more
FUJIFILM Irvine Scientific announced plans to open a third manufacturing facility located in Tilburg, Netherlands.
read more
Thursday, September 30, 2021
FUJIFILM Irvine Scientific, Inc., announced that it completed construction and started the commissioning phase of its new manufacturing facility in Tilburg, the Netherlands. The commissioning milestone marks the beginning of validating the facility ...
read more
Wednesday, December 01, 2021
FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, today announced the establishment of an Innovation and ...
read more
Monday, December 14, 2020
FUJIFILM Irvine Scientific has announced the launch of Sterile Express Media Service (SEMS), for small-scale, rapid production of non-GMP media tested for sterility.
read more
Wednesday, December 08, 2021
FUJIFILM Irvine Scientific, Inc., announced that its new manufacturing facility in Tilburg, the Netherlands is now open and fully operational. The facility provides state-of-the-art Life Science manufacturing and joins locations in the U.S. and Japan...
read more